VENTANA PD-L1 predictive assays assess the degree and likelihood of potential patient benefit from corresponding PD-1/PD-L1 immunotherapies. The link between assay results and patient benefit has been established and verified in studies.
VENTANA PD-L1 (SP263) Assay guides immunotherapy decisions by identifying:
Urothelial carcinoma (UC) patients most likely to benefit from IMFINZI (durvalumab) [FDA approved in the US]
The PD-L1 immunologic checkpoint
About PD-L1